Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

PhishPharm - Detail
  • Print
  • Share
  • E-mail
-
 
Title:  Depletion of florfenicol amine, marker residue of florfenicol, from the edible fillet of tilapia (Oreochromis niloticus x O. niloticus and O. niloticus x O. aureus) following florfenicol administration in feed.
 
Authors:  Gaikowski MP, Mushtaq M, Cassidy P, Meinertz JR, Schleis SM, Sweeney D, Endris RG
 
Drug:  Florfenicol
 
Fish species:  Tilapia (hybrid)
 
Date:  2010
 
Sample:  muscle+skin
 
Ave Weight (gm):  507
 
Ave Water temp (°C):  27
 
Water:  Freshwater
 
Dosage:  15 mg/kg 12d
 
Route:  PO
 
Comments:  Fish were sacrificed by electrocution. Fish used in this study included females that were gender-reversed as fry using methyltestosterone. Genotypic or phenotypic male Nile tilapia obtained for trial. The dosing period was extended for an additional 2 d (12 d total) because Nile tilapia did not consume > 75% of the feed offered on the first two days. Mean minimum daily dose estimated at 13.98 (range:9.8-14.9) mg/kg BW/d (93% target daily dose). Mean florfenicol amine (FFA) concentration 1d post-dosing=1.05 ug/g, 2d-post-dosing=0.47 ug/g, 4d post-dosing=0.30 ug/g, 7d post-dosing=0.14 ug/g, 14d post-dosing=<0.08 ug/g, 21d post-dosing = 0.13 ug/g, 28d post-dosing=ND. FFA half life=2.32d. Significant differences in FFA concentrations were not observed at any time point between nile and hybrid tilapia.
 
Metabolites:  Florfenicol amine
 
Citation:  Aquaculture 301:1-6
 
Link:  doi:10.1016/j.aquaculture.2010.01.020  Opens a new window
 
Genus Species:  Oreochromis niloticus x Oreochromis niloticus
 
Drug Class:  Antiobiotic-phenicol
 
t1/2-detail:  Metabolite halflife=2.32 d
 
Wt gm-detail:  507+/- 86 g
 
Water temp (°C)-detail:  27+/- 2C (25.8-27.0 C)
 
Dosage-detail:  15 mg/kg 12d
 
Method:  HPLC-UV
 
Authors-red:  Gaikowski MP, Mushtaq M, Cassidy P, Meinertz JR, Schleis SM, Sweeney D., Endris RG
 
-
-